FAP and colorectal carcinoma: Importantly, we have demonstrated that inhibition of this hypusination-dependent mechanism elicits significant therapeutic effects in preclinical models of CRC and FAP, thus representing a novel potential actionable target in these disorders (Fig. 5i).